Sapu Nano and Oncotelic have dosed the first patient in a Phase 1b clinical trial of Sapu003, an intravenous formulation of everolimus designed to treat advanced mTOR-sensitive solid tumors such as HR+/HER2- breast cancer and renal cell carcinoma. This trial aims to evaluate safety, tolerability, and preliminary anti-tumor effects with weekly IV dosing. The new formulation seeks to improve drug exposure and reduce side effects compared to oral everolimus. The study's progress marks a key step toward expanding treatment options for cancers with mTOR pathway involvement.
Cerebras Systems, an AI chip maker based in Sunnyvale, California, is set to go public on Nasdaq under the ticker CBRS on May 14, 2026, marking the first IPO from TSG Invest's Venture 50 Index. The company raised its IPO price range to $150-$160 per ...
Cerebras Systems, an AI chip maker known for its wafer-scale engine technology, is set to debut on Nasdaq under ticker CBRS, marking the first IPO from TSG Invest's Venture 50 Index. The company raised its IPO price range to $150-$160 per share due t...
Techstars has formed a strategic partnership with fintech platform Xendoo and accounting software Xero to offer startups a comprehensive financial operations solution. This collaboration aims to help early-stage companies maintain better financial vi...
The Gabelli Utility Trust Board approved monthly cash distributions of $0.05 per share for July, August, and September 2026, maintaining its fixed monthly payout policy. The Fund's shares currently trade at a premium to net asset value, which the Boa...
Nokia shares climbed 3.87% in premarket trading following the launch of new agentic AI capabilities aimed at improving home and broadband networks. The AI tools are designed to automate troubleshooting, enhance network operations, and accelerate fibe...
